Trial Profile
A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Zanubrutinib (Primary)
- Indications Marginal zone B-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms MAGNOLIA
- Sponsors BeiGene
- 15 Jun 2023 Final analysis presented at the 28th Congress of the European Haematology Association.
- 15 Jun 2023 Results of pooled analysis from NCT03846427 and NCT02343120 assessing unanchored MAIC to estimate the comparative efficacy of ZANU versus IBRU in R/RMZL presented at the 28th Congress of the European Haematology Association
- 06 Jun 2023 Results assessing matching-adjusted indirect comparison to estimate efficacy of zanubrutinib versus ibrutinib in relapsed/refractory marginal zone lymphoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.